Trial Profile
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination With Pembrolizumab in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs CTX-471 (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Compass Therapeutics
- 05 Jan 2024 Response in 5 patients observed, were presented in a Compass Therapeutics Media Release.
- 05 Jan 2024 According to a Compass Therapeutics media release, dose-escalation portion of the study has been fully enrolled and enrollment in the dose expansion cohorts has begun, 60 patients with melanoma, NSCLC and SCLC will be enrolled in the dose-expansion cohort, who will be randomized into two doses.
- 15 Mar 2023 According to Compass Therapeutics media release, initial combination results are expected in the second half of 2023.